3E Bioventures Capital
3E Bioventures Capital is a venture capital firm focused on life sciences, investing in global health innovators. The firm targets Biotech, including new drugs, modalities, and drug discovery platforms, as well as TechBio, which merges biology and technology to disrupt traditional paradigms. 3E Bioventures follows a science-driven, entrepreneur-friendly investment approach, collaborating with companies and research institutions to develop solutions for unmet medical needs. The firm's philosophy is encapsulated in its name, 3E: Expertise, Efficiency, Execution.
3E Bioventures Capital
Portfolio
A first-in-class biologic drug, an AXL-Fc fusion protein which acts as a trap for Gas6 AXL signaling which plays an important role in tumor metastasis and associated EMT mechanism.
#Biotech/New Drugs
A first-in-class biologic drug targeting an important innate immunity pathway, CD24 Siglec signaling.
#Biotech/New Drugs
Pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell.
#Biotech/New Drugs
Treating central nervous system disorders by targeting the cellular damage response mechanisms.
#Biotech/New Drugs
A clinical stage immuno-oncology company developing best-in-class CTLA-4 antibody and first-in-class CD24 antibody.
#Biotech/New Drugs
A first-in-class small molecule drug targeting LAT1, large amino acid transporter protein.
#Biotech/New Drugs